featured
Neoadjuvant Pembrolizumab and High-Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Pembrolizumab and High Dose Interferon Alfa-2b in Resectable Regionally Advanced Melanoma
Clin. Cancer Res 2021 Mar 22;[EPub Ahead of Print], YG Najjar, D McCurry, H Lin, Y Lin, Y Zang, D Davar, A Karunamurthy, JJ Drabick, RI Neves, LH Butterfield, MS Ernstoff, I Puzanov, JJ Skitzki, JM Bordeaux, IB Summitt, JO Bender, J Young Kim, B Chen, G Sarikonda, A Pahuja, J Tsau, Z Alfonso, C Laing, JF Pingpank, MP Holtzman, C Sander, A Rose, HM Zarour, JM Kirkwood, AA TarhiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.